| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | U.S. surgeon general has warned about alcohol and cancer risk. What should providers do? | - | FierceHealthcare | ||
| Do | Press Ganey: Where payers should be focusing their member experience efforts | - | FierceHealthcare | ||
| Do | 'It reminds me of Bitcoin': Healthcare execs split on ICHRAs | - | FierceHealthcare | ||
| Do | UnitedHealth, Amedisys ask court to dismiss DOJ's challenge to $3.3B merger deal | - | FierceHealthcare | ||
| Do | 2024 a mixed bag for health tech venture capital: HSBC report | - | FierceHealthcare | ||
| Do | NORTHWEST NATURAL GAS CO - 8-K, Current Report | - | SEC Filings | ||
| Do | Qomolangma Acquisition Corp. - 8-K, Current Report | - | SEC Filings | ||
| Do | Enad Global 7 AB: Enad Global 7 initiates a wind down of the operations in Toadman | 40 | GlobeNewswire (Europe) | As part of Enad Global 7's (EG7) efforts to deliver on the groups long term strategy, the Board of Directors has initiated the process to wind down the operations in Toadman. This decision does not... ► Artikel lesen | |
| Do | Xbrane Biopharma AB: Xbrane Biopharma appoints Jane Benyamin as acting Chief Financial Officer | 14 | GlobeNewswire (Europe) | Xbrane announces today that it has appointed Jane Benyamin as acting CFO as of January 9, 2025. As previously announced, the company's current CFO, Anette Lindqvist, is stepping down from the role of... ► Artikel lesen | |
| Do | Netum Group Oyj: Change in Netum Group Plc's Board of Directors and Management Team - new CEO Repe Harmanen to start in his position on 10 January 2025 | 9 | GlobeNewswire (Europe) | Netum Group Plc | Company announcement | 9 January 2025 at 3:00 p.m. EET
Change in Netum Group Plc's Board of Directors and Management Team - new CEO Repe Harmanen to start in his position on 10 January... ► Artikel lesen | |
| Do | H. Lundbeck A/S: Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD | 91 | GlobeNewswire (Europe) | H. Lundbeck A/S (Lundbeck) announces that the U.S. Food and Drug Administration (FDA) plans to host a Psychopharmacologic Drugs Advisory Committee (PDAC) meeting to seek input on issues related to the... ► Artikel lesen | |
| Do | Gatos Silver, Inc.: Gatos Silver Reports 2024 Production at the Top End of Guidance | 97 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Gatos Silver, Inc. (NYSE/TSX: GATO) ("Gatos Silver" or the "Company") today announced production results for the quarter and year ended... ► Artikel lesen | |
| Do | ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024 | 428 | GlobeNewswire (Europe) | PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| Do | Zefiro Methane Corp. Releases Updated Corporate Presentation Reflecting 2024 Growth | 117 | GlobeNewswire (Europe) | FORT LAUDERDALE, Fla., Jan. 09, 2025 (GLOBE NEWSWIRE) -- ZEFIRO METHANE CORP. (Cboe Canada: ZEFI) (Frankfurt: Y6B) (OTCQB: ZEFIF) (the "Company", "Zefiro", or "ZEFI"), an environmental services company... ► Artikel lesen | |
| Do | Aptose Biosciences, Inc.: Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial | 1.236 | GlobeNewswire (Europe) | SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced... ► Artikel lesen | |
| Do | Mural Oncology, Inc.: Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts | 82 | GlobeNewswire (Europe) | Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary... ► Artikel lesen | |
| Do | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) | 124 | GlobeNewswire (Europe) | Priority programs - NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis - set foundation for significant, near-term value creation Phase... ► Artikel lesen | |
| Do | NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 31 | GlobeNewswire (Europe) | NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| D-WAVE QUANTUM | 2.978 |
| BAYER | 2.400 |
| NEL | 2.376 |
| NVIDIA | 2.045 |
| EVOTEC | 1.641 |
| TESLA | 1.226 |
| DEUTSCHE LUFTHANSA | 1.131 |
| TUI | 1.126 |
| DEUTSCHE BANK | 1.010 |
| NOVO NORDISK | 1.008 |
| PLUG POWER | 997 |
| COMMERZBANK | 949 |
| RENK GROUP | 815 |
| VOLKSWAGEN | 781 |
| KONTRON | 731 |
| NORDEX | 675 |
| BYD | 661 |
| RHEINMETALL | 641 |
| RWE | 615 |
| BASF | 600 |
| BIONTECH | 594 |
| MERCEDES-BENZ | 587 |
| BP | 529 |
| MICROSTRATEGY | 500 |
| DEUTSCHE TELEKOM | 491 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
